Ultravist 0.623gm Infusion
By Ultravist
Rx
100ml Infusion in a Bottle

Composition
Iopromide(0.623gm)

Manufacturer - Zydus Cadila
Zydus Tower, Satellite Cross Roads,Ahmedabad – 380015 Gujarat, India.

Expires on or after
October, 2025

liver
When using Ultravist 0.623gm Infusion, it is important to exercise caution in individuals with severe liver disease. Patients with liver issues may require a dose adjustment for this infusion. It is recommended to consult your doctor before using Ultravist 0.623gm Infusion to ensure appropriate administration and safety.

kidney
Ultravist 0.623gm Infusion requires caution in severe kidney disease. Dosage adjustment may be necessary. Consult your doctor regarding its use.

alcohol
Consult your doctor when consuming alcohol with Ultravist 0.623gm Infusion.

driving
It is unclear if Ultravist 0.623gm Infusion impacts driving. Avoid driving if you have symptoms affecting focus and reaction time.

pregnancy
Ultravist 0.623gm Infusion is believed to be safe in pregnancy based on animal studies. Limited human studies are available, but show no major harmful effects.

breastfeeding
Caution Ultravist 0.623gm Infusion may not be safe during breastfeeding. Limited data indicates potential harm to the baby as the drug might pass into breastmilk.
Habit Forming | No |
Chemical Class | 4-Halobenzoic Acids Derivative |
Therapeutic Class | - |
Action Class | X ray contrast media (Diagnostic agents) |
₹1579.52
Inclusive of all taxes
Content verified by

Dr. Abdullah Khan
MBBS - General Medicine
Last update on 01-Oct-2024